Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c
Tweet
Share
E-mailGet Alerts ACRV Hot Sheet
Join SI Premium – FREE
Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.52), $0.23 better than the analyst estimate of ($0.75).
For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
- Jefferies sees metals breakout on currency concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
